The firm recognized $63.1 million in revenues and processed 162,807 tests in the second quarter 2018.
A team of researchers in Japan used a noninvasive prenatal testing platform to detect copy number alterations in about 20 percent of gynecological cancers they tested.
The company is using its informatics services business to inform internal diagnostic research and development efforts.
The partners will test PerkinElmer's Vanadis NIPT platform on samples from 2,650 women to determine detection and false positive rates.
The report states that using NIPD for trisomy 21 in high-risk women could "probably reduce" the total number of invasive tests though the data is incomplete.
Under the agreement, the companies plan to develop a customized solution that can be widely deployed for DNA sequencing.
Cooper took a $24.4 million impairment charge in the second quarter on the intangible assets it acquired in 2016 from carrier screening firm Recombine.
The UK-based noninvasive prenatal testing firm also said that it has raised £2.5 million in funding through a share subscription.
The firm said it would likely do a joint submission of its ctDNA assay to the FDA and CMS for approval and a national coverage determination.
The molecular diagnostics firm recognized $62.3 million in first quarter 2018 revenues, and it processed more than 164,000 tests.
The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.
Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.
Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.
In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.